<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423851</url>
  </required_header>
  <id_info>
    <org_study_id>NS-018-101</org_study_id>
    <nct_id>NCT01423851</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF</brief_title>
  <official_title>A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NS Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NS Pharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of orally administered
      NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis
      (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2 study that is currently enrolling JAK2 failures into the Phase 2 portion
      of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of NS-018 assessed by the type, frequency, seriousness and intensity of adverse events</measure>
    <time_frame>Throughout the study until 30 days after the last dose of study drug (patients with disease progression or no clinical benefit after 6 cycles [168 days] will be discontinued from the study)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Phase 1 and Phase 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish maximum tolerated dose of NS-018</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate response to NS-018 treatment using the International Working Group-Myeloproliferative Neoplasms Research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus, change in spleen size and bone marrow assessment</measure>
    <time_frame>Day 29, 57, 85, and every 84 days thereafter</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic parameters of NS-018 (Cmax, Tmax, AUC, t1/2 and accumulation ratio)</measure>
    <time_frame>Up to 24 hours post-dose on Day 1, 8, 15, 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase 1 and Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate pharmacodynamic correlates of NS-018</measure>
    <time_frame>Day 1, 8, 15, 29, 57, 85, and every 84 days thereafter</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase 1 and Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate quality of life assessments using Myelofibrosis Symptom Assessment Form (MF-SAF) for Phase 1 and the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) for Phase 2.</measure>
    <time_frame>Day 29, 85, and every 84 days thereafter</time_frame>
    <safety_issue>No</safety_issue>
    <description>Phase 1 and Phase 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-Polycythemia Vera Myelofibrosis</condition>
  <condition>Post-Essential Thrombocythemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Intervention: Drug: NS-018</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS-018</intervention_name>
    <description>Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).</description>
    <arm_group_label>Intervention: Drug: NS-018</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary myelofibrosis, post-PV MF, or post-ET MF that requires therapy

          -  MF patients must have received prior JAK2 inhibitor therapy, and been found to be
             intolerant, or refractory/relapsed from prior JAK2 inhibitor therapy, based on
             investigator assessment

          -  ≥18 years old

          -  ECOG Performance Status of ≤ 3

          -  Estimated life expectancy of ≥12 weeks

          -  Male or non-pregnant, non-lactating female patients

          -  Serum creatinine of ≤1.5 × the upper limit of normal (ULN)OR estimated creatinine
             clearance (CrCl) ≥ 40 ml/min/1.73 m2

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × the upper
             limit of normal (ULN) and total bilirubin ≤1.5 × ULN. If the total bilirubin is
             elevated between 1.5 x and 3 x ULN, patients with a direct bilirubin ≤ 1.5 X ULN are
             eligible during the Phase II portion.

          -  Absolute neutrophil count (ANC) &gt;1000/μL and Platelet count &gt; 25,000/μL

          -  QTcB ≤ 480 msec

          -  No MF-directed treatment for at least 2 weeks prior to initiation of NS-018,
             including any use of corticosteroids for Myelofibrosis symptom or blood count
             management. Low dose corticosteroids ≤ 10 mg/day prednisone or equivalent is allowed
             for non-myelofibrosis purposes.

        Exclusion Criteria:

          -  Active, uncontrolled systemic infection

          -  Patients with any unresolved toxicity greater than Grade 1 from previous anticancer
             therapy

          -  Potentially curative therapy is available

          -  Currently taking medication that is substantially metabolized by cytochrome P450
             (CYP) 1A2 or CYP3A4 or taking medication known to be strong inhibitors or inducers of
             CYP3A4

          -  Patients with a serious cardiac condition within the past 6 months

          -  Pregnant or lactating

          -  Radiation therapy for splenomegaly within 6 months prior to study entry

          -  Splenectomy (Phase 2 portion of the study only)

          -  Known HIV positive status

          -  Known active hepatitis, a history of viral hepatitis B or hepatitis C
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srdan Verstovsek, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, Houston, TX, 77030</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale Recruiting</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - All Mayo Clinic Locations</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Ruben A. Mesa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0698</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reilly Kidwell</last_name>
      <phone>858-534-4801</phone>
      <email>rkidwell@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Catriona Jamieson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Terns</last_name>
      <phone>312-695-1354</phone>
      <email>s-rindt@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Brady Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Pape</last_name>
      <phone>773-702-6206</phone>
      <email>lpape@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peggy Green</last_name>
      <phone>773-7702-0267</phone>
      <email>mgreen@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Olatoyosi Odenike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Patches</last_name>
      <email>Sarah_Patches@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Martha Wadleigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabeela Iqbal</last_name>
      <email>nabeela@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Moshe Talpaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Bauman</last_name>
      <email>rub9018@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Ritchie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, Department of Leukemia</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srdan Verstovsek, M.D., Ph.D.</last_name>
      <phone>713-745-3429</phone>
      <email>sverstov@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Srdan Verstovsek, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 24, 2015</lastchanged_date>
  <firstreceived_date>August 15, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keywords provided by NS Pharma, Inc.:</keyword>
  <keyword>JAK2 kinase inhibitor</keyword>
  <keyword>NS-018</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <keyword>Primary Myelofibrosis</keyword>
  <keyword>post-Polycythemia Vera Myelofibrosis</keyword>
  <keyword>post-Essential Thrombocythemia Myelofibrosis</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Thrombocythemia, Essential</keyword>
  <keyword>PMF</keyword>
  <keyword>post-PV MF</keyword>
  <keyword>post-ET MF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
